Niagen Bioscience launches 1st drug candidate for rare genetic diseases

Niagen Bioscience is moving from selling supplements to developing drugs, starting with an NAD+ therapy for rare genetic diseases.

Niagen Bioscience Inc., the Nasdaq-listed company known for NAD+ booster supplements, launched its first pharmaceutical program through a newly formed subsidiary, targeting accelerated aging and rare genetic diseases where no approved therapies exist.

The company announced the formal launch of the first drug candidate from NAD Pharmaceuticals Corp., its wholly owned subsidiary focused on developing therapies for rare diseases, according to a statement. Niagen did not disclose the specific indication, molecular target or development phase of the candidate.

The program centers on how NAD+, a coenzyme essential to energy metabolism, DNA repair, mitochondrial function and cellular stress responses, modulates disease pathways in rare genetic conditions. NAD+ levels decline with age, and researchers have linked the depletion to mitochondrial dysfunction in conditions such as Friedreich's ataxia and certain mitochondrial encephalopathies — areas where no FDA-approved therapies exist for many subtypes. The company's existing supplement business sells nicotinamide riboside, a precursor that boosts NAD+ levels, giving it manufacturing and formulation experience relevant to drug development.

The move marks a strategic shift for a company that built its business on consumer nutraceuticals. If the program advances to clinical trials and secures FDA orphan drug designation, Niagen could qualify for seven years of market exclusivity, tax credits covering up to 25% of clinical trial costs and waived application fees — incentives that have driven premium valuations for rare disease developers such as BioMarin Pharmaceutical Inc. and Ultragenyx Pharmaceutical Inc.

The pharmaceutical push comes as the broader NAD+ research field gains traction. Academic studies have linked declining NAD+ levels to aging, metabolic dysfunction and neurodegenerative diseases, creating a growing market for both supplements and potential therapeutics. ChromaDex Corp., which holds patents on nicotinamide riboside and trades on Nasdaq under CDXC, has built a substantial supplement business but has not crossed into drug development. Elysium Health, a privately held competitor, has also focused on the consumer channel. The difference for Niagen is its decision to pursue a regulated drug pathway, which could open a much larger addressable market if clinical data supports efficacy.

Niagen's decision to house the program in a separate subsidiary suggests the company may seek external partnerships or licensing deals to fund clinical development. Biotech startups targeting NAD+ pathways for rare diseases have attracted venture capital interest, though no NAD+-based therapy has reached FDA approval. The rare disease drug market was valued at roughly $280 billion globally in 2025, according to Evaluate Pharma, with orphan drugs accounting for about 20% of total prescription drug sales. Even a single approved orphan drug can generate peak sales of $500 million to $2 billion annually, depending on the indication and pricing.

For investors, the question is whether Niagen can execute a transition that has tripped up other supplement companies. The nutraceutical-to-pharma shift requires a different regulatory playbook, longer timelines and higher capital requirements. Niagen did not disclose its cash position or provide a timeline for clinical milestones. The company's shares trade on Nasdaq under NAGE. Investors will watch for details on the specific indication, preclinical data and financing plans in coming quarters.

This article is for informational purposes only and does not constitute investment advice.